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Abstract
Purpose In the treatment of patients with high-risk neuro-
blastoma, different doses of 131I-metaiodobenzylguanidine (131I-
MIBG) are administered at different time points during treat-
ment. Toxicity, mainly haematological (thrombocytopenia),
from 131I-MIBG therapy is known to occur in extensively
chemotherapy pretreated neuroblastoma patients. Up to
now, acute toxicity from 131I-MIBG as initial treatment has
never been studied in a large cohort. The aim of this retro-
spective study was to document acute toxicity related to up-
front 131I-MIBG.
Methods All neuroblastoma patients (stages 1–4 and 4S)
treated upfront with 131I-MIBG at the Emma Children’s Hos-
pital, Academic Medical Centre (1992 – 2008) were included
in this retrospective analysis. The acute toxicity (during ther-
apy) and short-term toxicity (1st month following therapy) of
the first two 131I-MIBG therapies were studied.
Results Of 66 patients (34 boys, 32 girls; median age
2.2 years, range 0.1 – 9.4 years), 49 had stage 4 disease, 5
stage 4S, 6 stage 3, 1 stage 2 and 5 stage 1. The median first
dose was 441 MBq/kg (range 157 – 804 MBq/kg). The
median second dose was 328 MBq/kg (range 113 –
727MBq/kg). The most frequently observed symptoms were
nausea and vomiting (21 %, maximum grade II). The main
toxicity was grade IV haematological, occurring only in
stage 4 patients, after the first and second 131I-MIBG thera-
pies: anaemia (5 % and 4 %, respectively), leucocytopenia
(3 % and 4 %) and thrombocytopenia (2 % and 4 %). No
stem cell rescue was needed.
Conclusion The main acute toxicity observed was haema-
tological followed by nausea and vomiting. One patient de-
veloped posterior reversible encephalopathy syndrome during
131I-MIBG therapy, possibly related to 131I-MIBG. We con-
sider 131I-MIBG therapy to be a safe treatment modality.
Keywords Neuroblastoma . 131I-MIBG therapy . Acute
toxicity
Introduction
Despite intense multimodality treatment, 5-year overall sur-
vival of patients with stage 4 neuroblastoma is only 30 % to
40 %. This poor prognosis has improved with the addition of
immune therapy with anti-GD2 antibody [1]. Current induc-
tion protocols for patients with high-risk neuroblastoma con-
sist of intensive chemotherapy regimens. However, if a par-
tial response is not achieved or residual bone marrow disease
persists, survival rates are below 10 %. This is probably due
to early drug resistance.
An alternative treatment modality for this patient popula-
tion is 131I-metaiodobenzylguanidine (131I-MIBG), a norepi-
nephrine analogue with specific affinity for neural crest cells.
Dr. J. de Kraker sadly passed away during this study.
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Phase II studies investigating 131I-MIBG in patients with
refractory or relapsed neuroblastoma have shown response
rates in the range 0 – 56 % [2]. In the Emma Children’s
Hospital, Academic Medical Centre (EKZ-AMC) patients
with high-risk neuroblastoma receive initial 131I-MIBG prior
to induction chemotherapy (upfront) to reduce tumour load,
while avoiding the induction of early drug resistance. This
targeted treatment is most effective in those with a moderate
to large tumour burden because the radiation from the beta-
emitter 131I-MIBG to the individual cell can penetrate
neighbouring cells with a mean radius in tissue of about
0.5 mm (crossfire effect). De Kraker et al. were the first to
report that 131I-MIBG therapy is effective in patients with
newly diagnosed high-risk neuroblastoma with a large tu-
mour mass and high uptake of the radiopharmaceutical [3].
In the current protocol of the Dutch Childhood Oncology
Group (DCOG NB2009) patients with high-risk neuroblas-
toma are being treated with two courses of upfront 131I-
MIBG therapy, followed by chemotherapy according to the
high-risk protocol of the Gesellschaft for Pädiatrische
Onkologie und Hämatologie (GPOH NB 2004).
Over the past 20 years, preceding the DCOG NB 2009
study, in our hospital neuroblastoma patients have been
treated with upfront 131I-MIBG, while other study groups
have predominantly used 131I-MIBG in patients with refrac-
tory and relapsed disease. Therefore, our cohort is unique to
study toxicity of 131I-MIBG only. Up to now, toxicity of 131I-
MIBG has mainly been reported in extensively pretreated
patients. From these studies it is known that 131I-MIBG can
cause haematological toxicity with severe and prolonged
thrombocytopenia. Toxicity of 131I-MIBG as first-line single
therapeutic agent has never been reported before in a large
cohort of patients. The aim of this retrospective study was to
investigate acute toxicity of upfront 131I-MIBG therapy in a
large cohort of neuroblastoma patients (stages 1–4 and 4S).
Material and methods
Patients
All patients (0 – 18 years old) with histologically proven
(ganglio)neuroblastoma of any stage (International Neuro-
blastoma Staging System) treated with upfront 131I-MIBG
between January 1992 and April 2008 at the EKZ-AMC or
the Netherlands Cancer Institute-Antonie van Leeuwenhoek
Hospital (NKI-AVL) were eligible for this retrospective
analysis. Patients with stage 4 disease were treated with
upfront 131I-MIBG, followed by induction chemotherapy
and autologous stem cell transplantation according to the
consecutive high risk protocols. In earlier days, patients with
stage 1 to 3 and stage 4S were treated with 131I-MIBG if they
had inoperable MIBG-positive lesions that were causing or
were in danger of causing organ dysfunction.
Study design
Clinical data concerning acute toxicity were retrospectively
collected from medical and nursing records of the first two
131I-MIBG therapies. 131I-MIBG was given according to the
protocol previously described by de Kraker et al. [3]. Fixed
doses were given; the first dose was generally 7,400 or
5,550 MBq and the second 5,550 or 3,700 MBq. Dose mod-
ifications were made based on age and stage. For the purpose
of this study we calculated dose per kilogram body weight.
Patients younger than 1 year were not sedated. Parents were
involved in the care of their child and therefore were required
to take potassium iodide 200 mg daily for 2 weeks, beginning
the day prior to their child’s 131I-MIBG therapy. Patients
remained in radiation protective isolation until the exposure
rate was less than 20 μSv/h, measured with a counter at a
distance of 1 m from the patient [3]. Whole-body exposure
dose was not measured. The parents were extensively in-
formed about the nature and precise elements of the treatment
and the differences from other strategies, and consent was
obtained prior to treatment.
Data collection
As well as general patient characteristics, we documented
tumour-related features and data regarding 131I-MIBG ther-
apy. In brief, the total number of 131I-MIBG therapies per
patient, dose (megabecquerels and millicuries), infusion
duration, medication (analgesics, sedatives, antiemetics and
thyroid protection), tube-feeding and the duration of radia-
tion protective isolation were recorded.
To assess acute toxicity caused by 131I-MIBG, we searched
for: symptoms during infusion and during radiation protective
isolation (catecholamine-induced, cardiovascular, pulmonary,
gastrointestinal, neurological, blood and lymphatic system and
general symptoms), hepatic and renal toxicity, haematological
toxicity, red blood cell and platelet transfusions, paediatric
consultations during radiation protective isolation and reasons
for premature discharge from radiation protective isolation.
Toxicity was scored according to the Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0. We report
the highest toxicity grade observed.
Statistical analysis
Correlations were tested with the Mann-Whitney U test
(presence of grade IV haematological toxicity versus131I-
MIBG dose), and Fisher’s exact test (presence of grade IV
haematological toxicity versus bone marrow involve-
ment at diagnosis).
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Results
Patients
We identified 121 neuroblastoma patients of any stage
(Supplementary Fig. 1). Of these patients, 13 were excluded
because of missing data and 42 because of pretreatment. The
characteristics of the remaining 66 patients are presented in
Table 1. Their median age was 2.2 years (range 0.1 – 9.4 years).
Most patients presented with symptoms typical of neuro-
blastoma such as abdominal distension, fever, fatigue, pain-
ful limbs and/or hypertension. At diagnosis, 36 of the 66
patients had hypertension (grade 2), which improved after
the first 131I-MIBG therapy (data not shown).
131I-MIBG therapy
Administered 131I-MIBG doses are shown in Table 2 (fixed
doses are shown in Supplementary Table 1). The median first
131I-MIBG dose was 430 MBq/kg in children younger than
12 months and 447 MBq/kg in children aged 12 months and
older, with a median of 441 MBq/kg (range 157 – 804
MBq/kg) in all patients. The median second dose was
430 MBq and 314 MBq, respectively, with a median of
328 MBq/kg (range 113 – 727 MBq/kg) in all patients.
During the first 131I-MIBG therapy, the median periods of
radiation protective isolation were 3 days in children youn-
ger than 12 months and 4 days in children aged 12 months
and older, with a median of 4 days (range 1 – 8 days). During
second therapy, the median periods were 4 and 4 days,
respectively, with a median of 4 days (range 2 – 7 days) in
all patients. Two patients were prematurely discharged from
radiation protective isolation on the day of 131I-MIBG infu-
sion because of serious adverse events (SAEs; see Table 7).
Toxicity during infusion
Because uptake of 131I-MIBG in the tumour can give symp-
toms of catecholamine excretion, both during infusion and
during radiation protective isolation symptoms related to
catecholamine excretion were scored. No symptoms related
to catecholamine excretion were reported in medical or nurs-
ing files, not even when the infusion duration was reduced
from 240 to 120 min in 1997 (data not shown). The only
symptom reported was grade II vomiting in one patient after
the first 131I-MIBG infusion (data not shown).
Toxicity during radiation protective isolation
During first radiation protective isolation period, catecholamine-
related symptoms (grade I sweating and pallor) occurred in 4
and 3 of the 66 patients, respectively (Table 3). No
catecholamine-related symptoms occurred during the second
period.
Nausea and vomiting (grade I and II) were the most
frequently reported symptoms. These symptoms were less
frequent after the second 131I-MIBG therapy (Table 3).
Vomiting was reported in 14 of 66 patients during first
radiation protective isolation period and in 5 of 52 during
the second period. Nausea was reported in 7 of 66 patients
and 3 of 52 patients, respectively.
Fever was reported in five patients (grade I or II) during
radiation protective isolation. The origin of the fever was
unknown (tumour fever) in three patients (two stage 4, one
stage 4S). Sepsis was reported in two patients (stage 4).
These two patients were treated during radiation protective
isolation, without the need for intensive treatment.
Pain medication (acetaminophen) was prescribed in 38 of
66 patients and in 16 of 52 patients before the start of the first
and second therapies, respectively (Supplementary Table 2).
Patients with neuroblastoma frequently suffer from Hutch-
inson syndrome with limping and irritability due to skeletal
metastases from the neuroblastoma. In our population pain
did not exceed grade 3 (data not shown). Sedative medica-
tion (chloral hydrate, histamine-blocking agents or benzodi-
azepines) was given to 41 of 66 patients during the first 131I-
MIBG therapy and 26 of 52 patient during second therapy
(Supplementary Table 2).





Age at diagnosis (years), median (range) 2.2 (0.1 – 9.4)







Genetic aberrations, n (%)
MYCN amplification 17/63 (27)
Chromosome 1p loss of heterozygosity 18/53 (34)
Urinary catecholamines elevated, n (%) 61/64 (95)
Lactate dehydrogenase >1,500 U/l, n (%) 13/64 (20)
Ferritin ≥143 ng/ml, n (%) 32/63 (51)
a Because of missing data, the total number of patients can vary;
reported are the actual number of patients with positive findings/total
number of patients with data
b International Neuroblastoma Staging System
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Respiratory symptoms due to abdominal masses im-
proved during and after the first 131I-MIBG therapy in most
patients. Three patients (stage 4) developed respiratory
symptoms during the first 131I-MIBG therapy, caused by
ascites, primary varicella infection and fever (one patient
each). Two of these patients (stage 4 and 4S) developed
respiratory failure. Further details of these SAEs are
presented in Table 7 (patients 41 and 74). No renal toxicity
was observed in 39 patients after the first 131I-MIBG therapy
(27 patients missing data) and in 40 patients after the second
therapy (12 patients missing data). Hepatic toxicity after the
first 131I-MIBG therapy was observed in 11 patients (seven
grade I, one grade II and three grade III; 38 patients missing
data). After the second 131I-MIBG therapy eight patients
showed grade I hepatic toxicity (28 patients missing data).
Haematological toxicity
Grade IV anaemia was seen in three patients after the first
131I-MIBG therapy and in two other patients after the second
therapy (Table 4). Two patients developed grade IV
leucocyte toxicity after the first 131I-MIBG therapy and two
after the second therapy. Two of these patient had a neutro-
penia, one after the first and second and one only after the
second therapy (for the time lines of neutrophil counts of
these patients, see Supplementary Fig. 2a).
One patient developed grade IV thrombocytopenia after the
first 131I-MIBG therapy and two after the second (for the time
lines of platelet counts of these patients, see Supplementary
Fig. 2b). All patients had their next treatment modality within
5weeks of the 131I-MIBG therapy. Haematological toxicity was
Table 3 Clinical symptoms of
toxicity mentioned in medical
and nursing records during radi-
ation protective isolation and af-
ter discharge (first 4 weeks after
131I-MIBG therapy). Toxicity
was scored according to CTCAE
version 4.0; the highest toxicity
grade was reported
Symptom Grades reported First therapy
(n = 66), n (%)
Second therapy
(n =52), n (%)
During isolation
Catecholamine-induced Flushes – 0 (0) 0 (0)
Sweating I 4 (6) 0 (0)
Pallor I 3 (5) 0 (0)
Cardiovascular Circulatory failure IV 1 (2) 0 (0)
Gastrointestinal Vomiting I, II 14 (21) 5 (10)
Nausea I, II 7 (11) 3 (6)
General Tumour fever I, II 3 (5) 0 (0)
Infection I, III 2 (3) 0 (0)
Neurological Seizures III 1 (2) 0 (0)
Pulmonary Dyspnoea III 1 (2) 0 (0)
Respiratory failure IV 2 (3) 0 (0)
After discharge
Blood and lymphatic system Epistaxis I 0 (0) 1 (2)
General Tumour fever I, II 1 (2) 0 (0)
Infection I, II, III 4 (6) 2 (4)
Pulmonary Dyspnoea I, II 2 (3) 0 (0)
Table 2 131I-MIBG therapy characteristics
First therapy Second therapy
Dose (MBq/kg) Radiation protective isolation (days) Dose (MBq/kg) Radiation protective isolation (days)
No. of patients with data available 61/66a 45/66 44/52b 27/52
<12 months of age 430 (268 – 804) 3 (1 – 6) 430 (289 – 727) 4 (4 – 5)
≥12 months of age 447 (157 – 740) 4 (1 – 8) 314 (113 – 573) 4 (2 – 7)
All patients 441 (157 – 804) 4 (1 – 8) 328 (113 – 727) 4 (2 – 7)
The data presented are medians (range)
a Of the five patients with unknown data, two (2.0 and 3.8 years of age) were treated with 7,400 MBq but with missing weight
b Of the eight patients with unknown data, one (2 years of age) was treated with 5,500 MBq but with missing weight
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only present in patients with bone marrow involvement at
diagnosis (7 of 49 patients). Patients without bone marrow
involvement did not have any grade IV haematological toxicity
(Table 5).There was no significant difference in the adminis-
tered first 131I-MIBG dose between patients with and without
haematological toxicity (P=0.269). Five patients were not in-
cluded in the analysis because of missing data.
At diagnosis (before the first 131I-MIBG therapy), 58 % of
patients (38/66) needed a red blood cell transfusion (Table 6).
After the first therapy, only 23 % (15/66) needed a red blood
cell transfusion and 23% (12/52) after the second. One of the
patients who needed a red blood cell transfusion had stage 1
disease and two had stage 4S disease; all others had stage 4
disease. The need for a platelet transfusion increased slightly
after 131I-MIBG therapy. One patient needed a platelet trans-
fusion at diagnosis, and four after the first and two after the
second therapy (all stage 4). One of these patients had grade
IVand three grade III thrombocytopenia. One patient needed
a platelet transfusion although there was no thrombocytope-
nia. Tumour invasion in the pulmonary artery caused major
thoracic bleeding in this patient (see paragraph ‘serious
adverse events’ and Table 7 (patient 29)).
Toxicity after discharge
Within 5 weeks of discharge seven patients presented with
general symptoms (Table 3). One had fever of unknown
origin (stage 4S), and six had grade I–III infection (four stage
4 and two stage 3): pneumonia, Staphylococcus aureus sep-
sis, S. epidermidis sepsis, infection of the catheter entry
point, urinary tract infection and a common cold (one patient
each). One of these six patients had grade IV leucocytopenia.
Two patients (stage 4) developed a gastrointestinal infection
without fever caused by rotavirus and Clostridium difficile
(not shown in Table 3, because they did not meet the CTCAE
criteria). Respiratory distress (grades I and II) was reported
in two patients (one stage 4, one stage 4S) and was caused by
sepsis and oedema. Epistaxis (grade I) was reported by one
patient and was caused by thrombocytopenia.
Serious adverse events
SAEs observed during radiation protective isolation or within
4 weeks of 131I-MIBG therapy are shown in Table 7. All four
patients had disseminated disease (one stage 4S) with MYCN
amplification; two patients also had chromosome 1p loss of
heterozygosity. Two patients were prematurely discharged
from radiation protective isolation. Patient 41 was an infant
at the start of therapy. Although under the age of 1 year, she
had high-risk disease (MYCN amplification). During the first
day of radiation protective isolation, emergency treatment was
indicated because the abdominal tumour mass was causing
respiratory distress. This patient experienced respiratory fail-
ure and needed mechanical ventilation, so she was transported
from the radiation protective isolation unit to the paediatric
intensive care unit (PICU). Subsequently she had circulatory
collapse. Resuscitation was ineffective and post mortem ex-
amination was refused by the parents. Patient 74 suffered from
hypertensive encephalopathy causing seizures on the first day
of radiation protective isolation. These seizures were treated
Table 4 Number (percentage) of patients with haematological toxicity scored according to CTCAE version 4.0; the highest toxicity grade was
reported
Toxicity First therapy (n = 66) Second therapy (n =52)
CTCAE grade Total Missing CTCAE grade Total Missing
I II III IV I II III IV
Haemoglobin 4 (6) 23 (35) 14 (21) 3 (5) 44 (67) 8 (12) 5 (10) 22 (42) 5 (10) 2 (4) 38 (73) 5 (10)
Leucocytes 14 (21) 15 (23) 4 (6) 2 (3) 35 (53) 8 (12) 9(17) 16 (31) 11 (21) 2 (4) 36 (69) 5 (10)
Platelets 16 (24) 3 (5) 6 (9) 1 (2) 15 (23) 10 (15) 13 (25) 6 (12) 4 (8) 2 (4) 19 (37) 7 (13)
Table 5 Grade IV haematological toxicity according to CTCAE
criteria vs. bone marrow involvement at diagnosis as evaluated by
trephine biopsy or MIBG scan
Grade IV haematological
toxicity
Bone marrow involvement at diagnosis
Present Absent Total
Present 7 0 7
Absent 42 17 59
Total 49 17 66








Red blood cells 38 (58) 15 (23) 12 (23)
Platelets 1 (2) 4 (6) 2 (4)
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with diazepam (benzodiazepine). Consequently, she experi-
enced respiratory failure and was admitted to the PICU. After
recovery, the hypertension remained difficult to control with
medication. She was treated within the standard arm of the
GPOHNB2004. Within 1 year of 131I-MIBG therapy she died
of progressive disease.
Despite 131I-MIBG therapy, disease progressed in two
other patients. At diagnosis tumour invasion caused major
bleeding in the thorax of patient 29. After stabilization of
vital functions, the first 131I-MIBG therapy was tolerated
well. However, this patient died 1 day after discharge from
radiation protective isolation because of uncontrollable arte-
rial lung bleeding caused by progressive disease. The throm-
bocyte count was within the normal range. Patient 53 had an
uneventful first and second 131I-MIBG course. One week
after the second course she developed progressive disease
with severe inferior vena cava syndrome, respiratory dis-
tress, restlessness and opisthotonus. Despite acute chemo-
therapeutic treatment, she died due to tumour progression
2 weeks after her second 131I-MIBG therapy.
Discussion
In newly diagnosed neuroblastoma patients, the most fre-
quently encountered toxicity of 131I-MIBG was haematolo-
gical, followed by nausea and vomiting. Although this was a
retrospective study, we believe that from this large cohort,
conclusions can be drawn.
Haematological toxicity
Until now, 131I-MIBG toxicity has predominantly been docu-
mented in patients with refractory or relapsed neuroblastoma
who have received extensive chemotherapy treatment before
131I-MIBG therapy. Toxicity of 131I-MIBG only has therefore
been difficult to determine. Haematological toxicity, the main
toxicity observed in this pretreated population, was mostly
severe and persistent thrombocytopenia [4, 5]. In our cohort of
neuroblastoma patients treated with upfront 131I-MIBG only,
grade IV thrombocytopenia occurred in only 1 % of patients
after the first therapy and in 3 % of patients after the second.
These percentages are lower than would be expected with
induction chemotherapy [6]. Besides, no episodes of major
bleeding due to thrombocytopenia were observed. Nowadays,
toxicity of 131I-MIBG is often related to the delivered whole-
body dose. Due to the nature of this retrospective cohort,
whole-body doses were not available for this study. However,
we did not find a correlation between administered 131I-MIBG
dose and grade IV haematological toxicity. Mastrangelo et al.
also recently investigated the toxicity of upfront 131I-MIBG
delivered in combination with chemotherapy (cisplatin, cyclo-
phosphamide, etoposide, vincristine, and doxorubicin) in 13
newly diagnosed neuroblastoma patients. Toxicity was only
haematological and considered acceptable [7].
Previous studies have suggested a correlation between
bone marrow invasion and 131I-MIBG-induced myelosup-
pression [4]. In our cohort we also found a correlation
between these two factors, and patients with grade IV anae-
mia, leucocytopenia or thrombocytopenia all had dissemi-
nated disease. Matthay et al. demonstrated the feasibility
without significant toxicity of high-dose (up to a cumulative
dose of 36 mCi/kg), rapid-sequence, double-infusion 131I-
MIBG with stem cell support in patients with refractory or
relapsed disease [8]. Although not the focus of this study, we
can report that in our study population no stem cell rescue
was required during or after the first two 131I-MIBG thera-
pies in these newly diagnosed patients, even after doses up to
814 MBq/kg. Induction chemotherapy, surgery, dose-intense
chemotherapy and autologous stem cell rescue were feasible
after 131I-MIBG therapy. Furthermore,131I-MIBG therapy
early in induction did not affect the yield of stem cell or
bone marrow harvest (data not shown).
Nonhaematological toxicity
As has been found in previous studies, nausea and vomiting
were the symptoms most often observed during radiation
protective isolation, without exceeding grade II, possibly
due to tube feeding and medication (potassium iodide) [9].
Infections occur frequently after induction chemotherapy
due to myelosuppression, and contribute significantly to
Table 7 Serious adverse events
Patient Stage Age (years) Biological markers Events
29 4 3.7 MYCN amplification Sepsis during isolation. After the first treatment arterial bleeding
in the thorax due to tumour invasion of blood vessels
41 4S 0.1 MYCN amplification Respiratory and circulatory insufficiency and subsequently died
53 4 2.3 MYCN amplification, chromosome
1p loss of heterozygosity
Severe inferior vena cava syndrome, respiratory distress,
restlessness and opisthotonus
74 4 6.1 MYCN amplification, chromosome
1p loss of heterozygosity
Respiratory insufficiency due to convulsions (caused by posterior
reversible encephalopathy syndrome) and anticonvulsive medication
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morbidity and mortality in neuroblastoma patients. Infec-
tions have also been reported during and after 131I-MIBG
therapy in heavily pretreated patients and in patients treated
with myeloablative 131I-MIBG therapy [8]. Matthay et al.
found infectious events (grade 3 or 4) in 10.9 % of patients
with refractory neuroblastoma [9]. In contrast, only a few
patients in our cohort were diagnosed with infections not
exceeding grade II in severity. As patients in our study
were chemotherapy-naive, they might have had better bone
marrow reserve. Patients with infections were not neutro-
penic and could be treated during radiation protective iso-
lation without the need for intensive treatment. The need
for pain medication decreases immediately after the first
131I-MIBG therapy. Therefore, 131I-MIBG is often used in
palliative care for pain reduction or relief of other tumour-
related symptoms [10]. During radiation protective isola-
tion, blood pressure was not frequently monitored. However,
when it became apparent that hypertensive episodes can occur
many hours after 131I-MIBG infusion this policy was changed
in our hospital. Currently blood pressure is monitored for at
least 48 h after administration of 131I-MIBG [10]. Foley
catheters are standard of care in some centres. We did not
use Foley catheters, and no renal or urinary toxicity was
observed [8, 9].
Serious adverse events
Four SAEs occurred during or directly after 131I-MIBG
therapy. In one patient posterior reversible encephalopathy
syndrome (PRES), a rare complication in paediatric oncolo-
gy patients, caused seizures. The PRES was presumably
caused by preexisting hypertension, but toxicity of 131I-
MIBG cannot be excluded. Kosmin et al. found a significant
association between adverse events during and 20 to 25 h
after 131I-MIBG infusion and a systolic blood pressure above
the 90th centile before 131I-MIBG infusion. One of the four
adverse events they describe was severe with seizures [11].
In the literature only two other cases of PRES have been
described in neuroblastoma patients, and none of these pa-
tients were treated with 131I-MIBG [12].
In conclusion, 131I-MIBG therapy has an acceptable safe-
ty profile if the seriously ill condition of this patient popula-
tion is taken into consideration. The main toxicity observed
in this cohort was haematological (grade IV) and nausea and
vomiting (maximum grade II). Thrombocytopenia occurred
in a few patients but did not result in episodes of major
bleeding.
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